BioToxTech Co

BioToxTech Co Cash Flow per Share

The Operating Cash Flow per Share of BioToxTech Co (086040.KQ) as of Oct 21, 2026 is 456.60 KRW. In the previous year, Operating Cash Flow per Share was -489.90 KRW — a change of -193.20% (higher).

Cash Flow per Share

456.60KRW

YoY

-193.20%

Last updated:

Operating Cash Flow per Share of BioToxTech Co is 2025 456.60 KRW. Operating Cash Flow per Share of BioToxTech Co was 2024 -489.90 KRW. It decreases by -193.20% higher compared to the previous year.

The BioToxTech Co Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
210.62 KRW
Jan 1, 2019
99.34 KRW
Jan 1, 2020
314.00 KRW
Jan 1, 2021
299.04 KRW
Jan 1, 2022
-90.07 KRW
Jan 1, 2023
-1,117.27 KRW
Jan 1, 2024
-489.90 KRW
Jan 1, 2025
456.60 KRW
The BioToxTech Co Cash Flow per Share history
YEARCash Flow per ShareYoY
456.60KRW-193.20%
-489.90KRW-56.15%
-1,117.27KRW+1,140.41%
-90.07KRW-130.12%
299.04KRW-4.77%
314.00KRW+216.08%
99.34KRW-52.83%
210.62KRW-49.39%
416.17KRW+14.49%
363.51KRW-761.92%
-54.92KRW-61.02%
-140.88KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Operating Cash Flow per Share of BioToxTech Co is 456.60 KRW in 2025.

Operating Cash Flow per Share of BioToxTech Co changed from -489.90 KRW to 456.60 KRW, representing a -193.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioToxTech Co

All Key Metrics — BioToxTech Co